The American Association of Clinical Endocrinologists recently released a statement offering guidance to physicians for the use of outpatient glucose monitoring for the management of patients with diabetes.
Analyses of the type of system and frequency of use for self-monitoring blood glucose or continuous glucose monitoring are offered in the statement. Individualized clinical management customized to each patient’s needs are encouraged.
“Although glucose monitoring alone is not adequate to promote optimal diabetes management, it plays a necessary and crucial role in preventing or delaying the complications inherent with this disease,” Timothy Bailey, MD, FACP, FACE, ECNU, co-chair of the consensus statement writing committee, said in the statement “In order to optimize the clinical management of diabetes, it is imperative that patients and health care professionals collaborate closely when adapting to glucose monitoring technology.”
George Grunberger, MD, FACP, FACE, president of AACE and writing committee co-chair, added: This includes health professionals’ education of patients regarding the interpretation and use of [glucose monitoring] data to help modify behaviors, enhance their ability to self-adjust therapy, and help them decide when to seek medical assistance.”
Bailey reports various financial ties with Abbot Laboratories, ACON Laboratories, Alere, Animas Corp., Bayer AG, Becton, Dickinson and Company, Bristol-Myers Squibb, Cebix, Dexcom, Eli Lilly and Co., GlaxoSmithKline, Halozyme, Insulet Corp., LifeScan, MannKind Corp., Medtronic, Merck & Co., Novo Nordisk, Orexigen, Sanofi and Tandem Diabetes Care. Grunberger reports various financial ties with AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., GlaxoSmithKline, Janssen Pharmaceuticals, Merck & Co., Novo Nordisk and Sanofi. Please see the full statement for a list of all other authors’ relevant financial disclosures.